Company intelligence / Profile preview

Masker MedTech

Malmö, Skåne, Sweden

Ownership: Private
Development stage: Other

Overview

Masker MedTech is developing 2MA1, an inhaled, modified soluble human ACE2 protein-based antiviral candidate that in preclinical SARS-CoV-2 mouse models significantly reduced mortality, weight loss, and systemic inflammation, and improved cell viability versus remdesivir, and is being advanced toward human clinical trials.[1]

Therapeutic areas: OncologyInfectious Diseases
Modalities: ProteinBiologic
Industry: Biotech

Drug pipeline

1 asset

2MA1

Preclinical

Partnerships

Lund UniversityVINNOVA

Beyond the preview

Go deeper on Masker MedTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Masker MedTech.

Explore the full profile